Log In Sign up
The largest database of trusted experimental protocols

Byl719

Manufactured by Cayman Chemical
Visit Supplier

BYL719 is a laboratory reagent produced by Cayman Chemical. It is a small molecule kinase inhibitor. The core function of BYL719 is to inhibit the activity of the PI3K-alpha isoform.

Automatically generated - may contain errors

Lab products found in correlation

Docetaxel, by Merck Group (1 mentions) Pd98059, by Cayman Chemical (1 mentions) Gefitinib, by Abcam (1 mentions) Gdc 0941, by Cayman Chemical (1 mentions) Bez235, by Novartis (1 mentions) Vincristine, by Merck Group (1 mentions) Fk866, by Merck Group (1 mentions) Temozolomide tmz, by Merck Group (1 mentions) Agi 5198, by Merck Group (1 mentions) Everolimus, by Cayman Chemical (1 mentions) Gdc 0068, by Cayman Chemical (1 mentions) Staurosporine, by Cayman Chemical (1 mentions) Mk 2206, by Adooq (1 mentions) Z vad fmk, by Adooq (1 mentions) Ly294002, by Adooq (1 mentions) Bkm120, by Cayman Chemical (1 mentions) Azd8186, by Cayman Chemical (1 mentions) Erk1 2, by Cell Signaling Technology (1 mentions) Epidermal growth factor (egf), by Merck Group (1 mentions) Tead1, by Cell Signaling Technology (1 mentions)

6 protocols using byl719

1

Pharmacological agents for cancer research

Check if the same lab product or an alternative is used in the 5 most similar protocols
BEZ235 was kindly provided by Novartis Pharma AG (Basel, Switzerland). Docetaxel was obtained from Sigma Aldrich (St. Louis, MO), gefitinib, and Ku0063794 from Biovision (Milpitas, CA), and PD-98059, GDC-0941, and BYL719 from Cayman Chemicals (Denver, CO). All compounds were diluted to stock solutions and stored according to supplier recommendations.
Koh K.X., Tan G.H., Hui Low S.H., Mohd Omar M.F., Han M.J., Iacopetta B., Soo R., Beloueche-Babari M., Bhattacharya B, & Soong R. (2017). Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis. Oncotarget, 8(66), 110133-110144.
+ Open protocol
+ Expand
2

Glioma Tumorsphere Culture and Chemotherapeutic Testing

Cited 3 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
This study was conducted in accordance with Declaration of Helsinki. All tumor and blood samples were collected with patient consent under protocols approved at Yokohama City University (YCU) Hospital and Massachusetts General Hospital (MGH) Institutional Review Boards. To create glioma tumorsphere lines, fresh tumor specimens were obtained from surgery and enzymatically dissociated with 0.1% of Trypsin and DNase. Tumorsphere lines were cultured in serum-free neural stem cell medium, as previously described (3 (link),25 (link),28 (link)). All tumorsphere lines were cryopreserved less than passage 3 to use for in vitro experiments. Temozolomide (TMZ, Sigma), Nimustine (ACNU, Tokyo Chemical Industry), Lomustine (CCNU), Procarbazine (Sigma), Vincristine (Sigma), FK866 (Sigma), LY294002 (Sellek), GDC-0068 (Cayman), BYL719 (Cayman), Everolimus (Cayman), and AGI-5198 (Sigma) were used.
Tateishi K., Nakamura T., Juratli T.A., Williams E.A., Matsushita Y., Miyake S., Nishi M., Miller J.J., Tummala S.S., Fink A.L., Lelic N., Koerner M.V., Miyake Y., Sasame J., Fujimoto K., Tanaka T., Minamimoto R., Matsunaga S., Mukaihara S., Shuto T., Taguchi H., Udaka N., Murata H., Ryo A., Yamanaka S., Curry W.T., Dias-Santagata D., Yamamoto T., Ichimura K., Batchelor T.T., Chi A.S., Iafrate A.J., Wakimoto H, & Cahill D.P. (2019). PI3K/AKT/mTOR pathway alterations promote malignant progression and xenograft formation in oligodendroglial tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 25(14), 4375-4387.
+ Open protocol
+ Expand
3

Evaluating Small Molecule Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
MK-2206 (A10003), RAD001 (A10374), CAL-101 (A10172), LY294002 (A10547), and z-VAD-FMK (A12373) were purchased from AdooQ Biosciences. BAY 80-6946 (MedChemExpress, HY-15,346), BYL719 (Cayman Chemical, 16986), NVP-BGT226 (Cayman Chemical, 22142), Staurosporine (Cayman Chemical, 81590), and GSK2126458 (Cayman Chemical, 17377) were purchased from vendors.
Hung M.C., Wang W.P, & Chi Y.H. (2022). AKT phosphorylation as a predictive biomarker for PI3K/mTOR dual inhibition-induced proteolytic cleavage of mTOR companion proteins in small cell lung cancer. Cell & Bioscience, 12, 122.
+ Open protocol
+ Expand
4

Prostate Cancer Cell Line Maintenance and PI3K Inhibition

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Prostate cancer cell LNCaP, C4-2, 22RV1, DU145 and PC-3 lines were maintained in a humidified atmosphere of 5% CO2, RPMI1640 media supplemented with 10% fetal bovine serum (FBS) and antibiotics. LNCaP/shPIK3CB#3 cell subline was established by stable transfection with a pU6+2-p110βshRNA vector as reported previously (13 (link)). C4-2B and its MDV3100-resistant subline cells (C4-2B/MDV-R) were obtained from Dr Allen Gao at UC Davis (29 (link)). TGX221 and its analogs were synthesized in house as described previously (28 ) and the aqueous solubility assay was conducted as reported (30 (link)). PI3K inhibitors including BKM120 (catalog #11587), BYL719 (catalog #16986), AZD8186 (catalog #17384), AZD6482 (catalog #15250), GSK2636771 (catalog #17380) and Akt inhibitor VIII (AKT-i8, catalog #14870) were purchased from Cayman Chemicals (Ann Arbor, MI). Antibodies for p110α (clone C73F8), p110β (clone C33D4), p110γ (clone D55D5), VPS34 (clone D4E2), Cyclin D1 (clone 92G2), CDK6 (clone DCS83), p27kip1 (catalog #2552), pan-Akt (clone C67E7), phospho-Akt S473 (clone D9E) and T308 (clone 244F9) were obtained from Cell Signaling (Danvers, MA). Antibody for β-Actin (clone AC-15) was purchased from GeneTex Inc (Irvine, CA). Secondary antibodies for mouse and rabbit IgG as well as chemiluminescent reagent kit were purchased from Santa Cruz Biotech (Santa Cruz, CA).
He C., Duan S., Dong L., Wang Y., Hu Q., Liu C., Forrest M.L., Holzbeierlein J.M., Han S, & Li B. (2017). Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells. The Prostate, 77(11), 1187-1198.
+ Open protocol
+ Expand
5

Antibodies for EGFR-Hippo Signaling Study

Check if the same lab product or an alternative is used in the 5 most similar protocols
Anti-pEGFR (Y1068) (#2234, 1:5000), EGFR (#4267, 1:5000), pYAP (S127) (#4911, 1:2000), YAP (#14074, 1:1000), YAP/TAZ (#8418, 1:1000), pLATS1 (T1079) (#8654, 1:1000), LATS1 (#3477, 1:1000), LATS2 (#5888, 1:1000), pMST1/2 (T183/180) (#3681, 1:1000), MST1 (#3682, 1:1000), pMOB1 (T35) (#8699, 1:1000), MOB1 (#13730, 1:1000), TEAD1 (#12292, 1:1000), HA-tag (#3724, 1:10000), Myc-tag (#2276, 1:5000), FLAG-tag (#2368, 1:5000), GST-tag (#2624, 1:10000), pTyrosine (P-Y-100) (#9411, 1:2000), CTGF (#86641, 1:1000), CYR61 (#14479, 1:1000), pERK1/2 (T202/Y204) (#4370, 1:10000), ERK1/2 (#4696, 1:10000), pAKT (S473) (#4060, 1:5000), AKT (#9272, 1:5000), pS6 (S235/236) (#4858, 1:10000), S6 (#2217, 1:10000), PARP (#9542, 1:1000), GRB2 (#36344, 1:1000), β-actin (#4967, 1:5000) were purchased from Cell Signaling Technology (MA).
EGF (#E9644) was purchased from Sigma-Aldrich Inc (MO). BYL719 (#16986) was purchased from Cayman Chemical (MI).
Ando T., Arang N., Wang Z., Costea D.E., Feng X., Goto Y., Izumi H., Gilardi M., Ando K, & Gutkind J.S. (2021). EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1. Communications Biology, 4, 1237.
+ Open protocol
+ Expand
6

Gastric Cancer Cell Lines for Research

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
The EBV+ gastric cancer cell line YCCEL1 was obtained from Elliott Kieff. The EBV+ cell line SNU719 was obtained from Adam Bass. The EBV− gastric cancer cell line HGC-27 was obtained from Sigma, SNU-1 and SNU-16 were from ATCC. HEK-293T was obtained from ATCC. Cell lines with stable Streptococcus pyogenes Cas9 expression were generated by lentiviral transduction and blasticidin selection (5 mg/mL), as previously described 85 (link). Cells were cultured in a humidified incubator with 5% CO2 at 37°C. The cells were routinely tested and certified as mycoplasma-free using the MycoAlert kit (Lonza).
YCCEL1 cells were grown in Eagle’s Minimum Essential Medium (EMEM) medium (ATCC) with 10% fetal bovine serum (FBS, Gibco). SNU719 and SNU16 cells were grown in RPMI 1640 medium (Gibco, Life Technologies) with 10% FBS. 293T was grown in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% FBS. HGC-27 were grown in EMEM (ATCC) with 2mM Glutamine (Gibco, Life Technologies), 1% Non- Essential Amino Acids (NEAA, Gibco, Life Technologies), and 10% FBS. BYL719 (Alpelisib, Cat#16986, Cayman chemical) was used at 0.5mM. Antibodies used in the study are listed in the Reporting Summary.
Wang Y., Guo R., Piedras B.I., Tang H.Y., Asara J.M., Tempera I., Lieberman P.M, & Gewurz B.E. (2024). The CTLH Ubiquitin Ligase Substrates ZMYND19 and MKLN1 Negatively Regulate mTORC1 at the Lysosomal Membrane. Research Square.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!